Would you like to learn more about the process of developing new drugs to treat pulmonary hypertension (PH)? Check out the latest issue of the Pulmonary Hypertension Association’s (PHA’s) official journal, Advances in Pulmonary Hypertension, now available online. The issue addresses aspects of the drug development process.
In “Patient Perspective: Going Through a Clinical Trial,” Lena Bolivar shares her experience in a Stanford University clinical trial while awaiting a lung transplant. Other articles discuss new drug development targets, efficacy of clinical trials, and goals that better reflect patients’ quality of life.
In “Pulmonary Hypertension Roundtable: Drug Development and Negative Clinical Trial Results,” guest editors Mark Nicolls, M.D., of Stanford University in California and Marc Humbert, M.D., of Paris-Saclay University in France moderate a Q&A on obstacles to developing new PH treatments.
Read this free publication.
For more insight, attend our PHA Connects event, “Understanding the PH Drug Pipeline,” at 4 p.m. EDT Friday, Sept. 25.
